Alector(NASDAQ) ALEC

Market Cap$303.71M

Since IPO (2019)-85%

5 Year-90%

1 Year+5%

1 Month+80%

$2.73

+13.75%

+0.33Today

After hours$2.77+$0.04 (+1.47%)

Alector last closing stock price
Metric	Price	Date
Last close	USD 2.72	2026-09-02

Alector stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+10.57%	USD 2.46	2026-08-26
1 month	+80.13%	USD 1.51	2026-08-03
3 month	+50.28%	USD 1.81	2026-06-04
Year to date	+74.36%	USD 1.56	2025-12-31
1 year	+5.02%	USD 2.59	2025-09-02
3 year	-51.17%	USD 5.57	2023-09-01
5 year	-89.79%	USD 26.64	2021-09-03
Since inception	-84.89%	USD 18.00	2019-02-07

Alector Financials at a Glance

Market Cap

$303.71M

Revenue (TTM)

$13.86M

Net Income (TTM)

-$117.85M

EPS (TTM)

-$1.09

P/E Ratio

-2.49

Dividend

$0.00

Beta (Volatility)

1.67 (High)

Dividend

$0.00

Beta (Volatility)

1.67 (High)

Price

$2.73

Volume

27.23

Open

$2.40

Price

$2.73

Volume

27.23

Open

$2.40

Previous Close

$2.72

Daily Range

$2.40 - $2.76

52-Week Range

$1.09 - $3.40

Estimated Earnings Date

Nov 5, 2026

Dividend

$0.00

Beta (Volatility)

1.67 (High)

Price

$2.73

Volume

27.23

Open

$2.40

Previous Close

$2.72

Daily Range

$2.40 - $2.76

52-Week Range

$1.09 - $3.40

Estimated Earnings Date

Nov 5, 2026

ALEC News

What Company Will Eli Lilly Buy Next?

David HaenJan 23, 2020

Biotech’s Year-End To-Do List

David HaenDec 7, 2019

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alector

Alector, Inc. makes medicines for brain diseases like Alzheimer's. Its treatments help the brain's immune system stop damage. These therapies reach the brain easier than standard drugs.

New Ways to Treat the Brain

AL137 Program: Antibody treatment designed to clear toxic plaques in the brain; targeted for patients with Alzheimer's disease.
ABC-Enabled siRNA: Technology platform used to block the production of harmful proteins in brain cells.
AL050 Program: Enzyme therapy in development for patients with genetic mutations linked to Parkinson's disease and Lewy body dementia.
Alector Brain Carrier: Specialized delivery tool that helps drugs reach targets inside the central nervous system.

Recent Strategic Shifts

Selected AL137 as the lead candidate for Alzheimer's disease treatment in 2026.
Ended the long-term research and development partnership with AbbVie in February 2025.
Received a termination notice for its global collaboration agreement with GSK in July 2026.
Discontinued the Phase 2 trial for the drug nivisnebart in April 2026 after poor results.
Reduced total staff numbers by approximately 47% in October 2025 to cut costs.

Crossing the Brain Barrier

Alector uses its platform to deliver medicines like enzymes directly into the brain. This approach aims to stop brain decay by fixing the body's own immune cells.

A Look at the Books

Collaboration revenue was $3.3 million for the three-month period ended June 30, 2026.
Net loss was $23.0 million for the three-month period ended June 30, 2026.
Research and development expenses were $19.5 million for the three-month period ended June 30, 2026.
Cash, cash equivalents, and marketable securities totaled $172.8 million as of June 30, 2026.
Accumulated deficit reached $1,018.0 million by the end of June 2026.

Evolution of the Business

Alector has shifted to new brain therapies after losing major partnerships and clinical trials. Future success depends on moving early drug candidates through human testing using its delivery platform.

AI Generated • Aug 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

103

CEO

Arnon Rosenthal, PhD

Website

www.alector.com

Headquarters

South San Francisco, CA 94080, US

ALEC Financials

Key Financial Metrics (TTM)

Gross Margin

-360.92%

Operating Margin

-914.56%

Net Income Margin

-850.13%

Return on Equity

-531.04%

Return on Capital

-218.01%

Return on Assets

-58.10%

Earnings Yield

-40.16%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$303.71M

Shares Outstanding

111.66M

Volume

27.23

Avg. Volume

995.99K

Financials (TTM)

Gross Profit

-$50.03M

Operating Income

-$126.79M

EBITDA

-$107.84M

Operating Cash Flow

-$158.23M

Capital Expenditure

-$160.00K

Free Cash Flow

-$158.39M

Cash & ST Invst.

$172.80M

Total Debt

$32.76M

Alector Performance Analysis

Alector annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 133,617,000	-35.5%
2023	2023-12-31	USD 97,062,000	-27.4%
2024	2024-12-31	USD 100,558,000	3.6%
2025	2025-12-31	USD 21,045,000	-79.1%

Alector sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-58.6%
Q4	2025-12-31	91.3%
Q1	2026-03-31	-83.2%
Q2	2026-06-30	217.4%

Alector annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.62	257.8%
2023	2023-12-31	USD -1.56	-3.7%
2024	2024-12-31	USD -1.23	-20.9%
2025	2025-12-31	USD -1.39	12.6%

Alector sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-13.3%
Q4	2025-12-31	N/A
Q1	2026-03-31	38.2%
Q2	2026-06-30	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$3.32M

-57.8%

Gross Profit

$3.32M

+116.8%

Gross Margin

100.00%

N/A

Market Cap

$303.71M

N/A

Market Cap/Employee

$2.95M

N/A

Employees

103

N/A

Net Income

-$22.99M

+24.7%

EBITDA

-$18.73M

+31.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$172.80M

-43.8%

Total Debt

$32.76M

-17.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$13.70M

-55.2%

Short Term Debt

$19.06M

+114.0%

Return on Assets

-58.10%

N/A

Return on Invested Capital

-75.19%

N/A

Free Cash Flow

-$34.25M

+30.2%

Operating Cash Flow

-$34.22M

+30.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

FATEFate Therapeutics, Inc.

FATEFate Therapeutics, Inc.$2.45+0.82%

IRDOpus Genetics, Inc.

IRDOpus Genetics, Inc.$4.45+16.19%

ABOSAcumen Pharmaceuticals, Inc.

ABOSAcumen Pharmaceuticals, Inc.$3.10+6.16%

PEPGPepGen Inc.

PEPGPepGen Inc.$3.18+1.92%

CRBPCorbus Pharmaceuticals Holdings, Inc.

CRBPCorbus Pharmaceuticals Holdings, Inc.$11.48+1.77%

NKTXNkarta, Inc.

NKTXNkarta, Inc.$2.77+2.41%

MOLNMolecular Partners AG

MOLNMolecular Partners AG$4.07-5.02%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

BIAFbioAffinity Technologies

BIAFbioAffinity Technologies$9.75+0.48%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$51.83-0.01%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$106.35+0.00%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$69.60+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.37+0.00%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$39.71-0.01%

NOKNokia

NOKNokia$9.84-0.01%

Questions About ALEC

What is the current price of Alector?

Alector is trading at $2.72 per share.

What is the 52-week range for Alector?

Over the past 52 weeks, Alector has traded between $1.09 and $3.40.

How much debt does Alector have?

As of the most recent reporting period, Alector reported total debt of $32.76M.

How much cash does Alector have on hand?

Alector reported $59.92M in cash and cash equivalents in its most recent financial results.

What is Alector’s dividend yield?

Alector does not currently have a dividend yield.

Alector(NASDAQ) ALEC

Alector Financials at a Glance

ALEC News

Alector (ALEC) Q2 Revenue Falls 48%

Why Alector Shares Are Diving Today

Why Alector Zoomed 12% Higher Today

Why Alector Blasted Higher Today

Don't Miss What Sent These 2 Little-Known Nasdaq Newsmakers Soaring

Why Alector Is Tumbling 28.7% Today

What Company Will Eli Lilly Buy Next?

Biotech’s Year-End To-Do List

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Alector

New Ways to Treat the Brain

Recent Strategic Shifts

Crossing the Brain Barrier

A Look at the Books

Evolution of the Business

ALEC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Alector Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ALEC

What is the current price of Alector?

What is the 52-week range for Alector?

How much debt does Alector have?

How much cash does Alector have on hand?

What is Alector’s dividend yield?

Premium Investing Services